Ann: CEO Letter to Shareholders, page-5

There are some good signals in the newsletter. Vitiligo on track for Q4 enrolment completion - so even some room for early completion here according to scheduled 12/24 completion on clinical trials. VP perhaps aiming to be added to EPP label which would be big if they pulled it off, but a similar poor attempt with adolescents (which is still ongoing) doesn't inspire confidence, however if CUV040 is strong then who knows. New analysts apparently going to come on board which is a positive when most current analysts have PTs mid $20s just on EPP and one with Vitiligo priced in is ~$50PT.

Of course the mandatory weirdness was there with some jumbled sentences and multiple spelling mistakes, but at least they have hired some journalists. Never heard CSL talk about hiring journalists, I have heard CSL previous great CEO quoted as saying the share price is the scorecard. Lets see what comes of 2024, Stroke is another one, could be huge if CUV803 goes well on severe stroke patients and they get next trial rolling.

All IMO DYOR